{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:19:43Z","timestamp":1740374383151,"version":"3.37.3"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.esmoop.2024.104129","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T12:55:55Z","timestamp":1738673755000},"page":"104129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy, safety, and pharmacokinetics of eribulin as monotherapy or in combination with irinotecan for patients with pediatric rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, or Ewing sarcoma"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0368-7883","authenticated-orcid":false,"given":"M.","family":"Casanova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.M.","family":"Albert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0421-8862","authenticated-orcid":false,"given":"F.","family":"Bautista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1721-1520","authenticated-orcid":false,"given":"S.C.","family":"Borinstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8344-4365","authenticated-orcid":false,"given":"S.","family":"Bradfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bukowinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1509-6925","authenticated-orcid":false,"given":"Q.","family":"Campbell-Hewson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3602-1375","authenticated-orcid":false,"given":"D.S.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7813-5568","authenticated-orcid":false,"given":"A.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0250-6043","authenticated-orcid":false,"given":"G.M.","family":"Milano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.V.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8775-6710","authenticated-orcid":false,"given":"N.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7116-0605","authenticated-orcid":false,"given":"C.A.","family":"Pratilas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6426-7423","authenticated-orcid":false,"given":"A.","family":"Rubio-San-Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9614-0811","authenticated-orcid":false,"given":"R.","family":"Windsor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Majid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Paoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Kontny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2020","series-title":"German childhood cancer registry\u2013annual report 2019 (1980-2018)","author":"Erdmann","key":"10.1016\/j.esmoop.2024.104129_bib1"},{"year":"2023","series-title":"NCCR\u2217Explorer: an interactive website for NCCR cancer statistics","key":"10.1016\/j.esmoop.2024.104129_bib2"},{"year":"2024","series-title":"Ewing Sarcoma","author":"Durer","key":"10.1016\/j.esmoop.2024.104129_bib3"},{"issue":"6","key":"10.1016\/j.esmoop.2024.104129_bib4","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/pbc.23252","article-title":"Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database","volume":"57","author":"Ferrari","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2024.104129_bib5","first-page":"804","article-title":"Relapsed rhabdomyosarcoma","volume":"10","author":"Heske","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"11","key":"10.1016\/j.esmoop.2024.104129_bib6","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/annonc\/mdg457","article-title":"Therapy and survival after recurrence of Ewing\u2019s tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997","volume":"14","author":"Bacci","year":"2003","journal-title":"Ann Oncol"},{"year":"2023","series-title":"Irinotecan","author":"Reyhanoglu","key":"10.1016\/j.esmoop.2024.104129_bib7"},{"year":"2023","series-title":"Vincristine","author":"Awosika","key":"10.1016\/j.esmoop.2024.104129_bib8"},{"issue":"8","key":"10.1016\/j.esmoop.2024.104129_bib9","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3174\/ajnr.A2170","article-title":"Temozolomide (Temodar)","volume":"31","author":"Wesolowski","year":"2010","journal-title":"AJNR Am J Neuroradiol"},{"issue":"27","key":"10.1016\/j.esmoop.2024.104129_bib10","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1200\/JCO.21.00124","volume":"39","author":"Defachelles","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2024.104129_bib11","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/pbc.24621","article-title":"Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma","volume":"60","author":"Raciborska","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2024.104129_bib12","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","article-title":"The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth","volume":"4","author":"Jordan","year":"2005","journal-title":"Mol Cancer Ther"},{"issue":"10028","key":"10.1016\/j.esmoop.2024.104129_bib13","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Schoffski","year":"2016","journal-title":"Lancet"},{"year":"2022","series-title":"Halaven\u00ae (eribulin mesylate) [prescribing information]","key":"10.1016\/j.esmoop.2024.104129_bib14"},{"issue":"8","key":"10.1016\/j.esmoop.2024.104129_bib15","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/pbc.24517","article-title":"Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program","volume":"60","author":"Kolb","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2024.104129_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27066","article-title":"A\u00a0phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: a Children\u2019s Oncology Group Phase 1 Consortium study (ADVL1314)","volume":"65","author":"Schafer","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2024.104129_bib17","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-19-1822","article-title":"Evaluation of eribulin\u00a0combined with irinotecan for treatment of pediatric cancer xenografts","volume":"26","author":"Robles","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2024.104129_bib18","article-title":"A\u00a0phase I\/II study of eribulin mesilate (ERI) plus irinotecan (IRI) in children with refractory or recurrent solid tumors","volume":"38","author":"Casanova","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2024.104129_bib19","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1470-2045(11)70230-3","article-title":"Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes","volume":"12","author":"Sch\u00f6ffski","year":"2011","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.104129_bib20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/jjco\/hyw175","article-title":"Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma","volume":"47","author":"Kawai","year":"2017","journal-title":"Jpn J Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2024.104129_bib21","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/jcph.315","article-title":"Population pharmacometric analyses of eribulin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes","volume":"54","author":"Majid","year":"2014","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.esmoop.2024.104129_bib22","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1002\/cncr.10600","article-title":"Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma","volume":"94","author":"Casanova","year":"2002","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2024.104129_bib23","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/cncr.21629","article-title":"Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma","volume":"106","author":"Bisogno","year":"2006","journal-title":"Cancer"},{"issue":"31","key":"10.1016\/j.esmoop.2024.104129_bib24","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.19.00576","article-title":"Randomized phase II trial of bevacizumab or temsirolimus in combination with chemotherapy for first relapse rhabdomyosarcoma: a report from the Children\u2019s Oncology Group","volume":"37","author":"Mascarenhas","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.104129_bib25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13569-015-0035-x","article-title":"Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?","volume":"5","author":"Wagner","year":"2015","journal-title":"Clin Sarcoma Res"},{"issue":"7","key":"10.1016\/j.esmoop.2024.104129_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31009","article-title":"Event-free survival in relapsed and refractory rhabdomyosarcoma treated on cooperative group phase II trials: a report from the Children\u2019s Oncology Group","volume":"71","author":"Metts","year":"2024","journal-title":"Pediatr Blood Cancer"},{"year":"2024","series-title":"Camptosar\u00ae (irinotecan hydrochloride) [prescribing information]","key":"10.1016\/j.esmoop.2024.104129_bib27"},{"issue":"3","key":"10.1016\/j.esmoop.2024.104129_bib28","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bcp.12143","article-title":"Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia","volume":"76","author":"van Hasselt","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.104129_bib29","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/cancers13030498","article-title":"Desmoplastic small round cell tumor: a review of main molecular abnormalities and emerging therapy","volume":"13","author":"Mello","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.esmoop.2024.104129_bib30","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.049649","article-title":"Effectiveness of irinotecan plus trabectedin on a desmoplastic small round cell tumor patient-derived xenograft","volume":"16","author":"Zuco","year":"2023","journal-title":"Dis Model Mech"},{"issue":"9","key":"10.1016\/j.esmoop.2024.104129_bib31","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/CAD.0000000000000536","article-title":"Clinical activity of eribulin in advanced desmoplastic small round-cell tumor","volume":"28","author":"Emambux","year":"2017","journal-title":"Anticancer Drugs"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924019008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924019008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T11:21:40Z","timestamp":1740309700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924019008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2059702924019008"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.104129","relation":{},"ISSN":["2059-7029"],"issn-type":[{"type":"print","value":"2059-7029"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, safety, and pharmacokinetics of eribulin as monotherapy or in combination with irinotecan for patients with pediatric rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, or Ewing sarcoma","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.104129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"104129"}}